Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Zacks Short Term Rating on Rockwell Medical, Inc. (NASDAQ:RMTI) - News Watch International |
 |
 |
|
As much as 4 analysts have advised buy on Rockwell Medical, Inc. (NASDAQ:RMTI) with an average broker rating of 2. Research Analysts at Zacks has the shares a rating of 3, which implies that the firms recommendation is Neutral on the company. Rockwell Medical, Inc. (NASDAQ:RMTI): 4 Analyst have given the stock of Rockwell Medical, Inc. (NASDAQ:RMTI) a near short term price target of $16.25. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $9.18. The higher price target estimate is at $26 while the lower price estimates are fixed at $4. The company shares have rallied 26.08% in the past 52 Weeks. On June 16, 2015 The shares registered one year high of $14.95 and one year low was seen on December 15, 2014 at $8.1. The 50-day moving average is $11.47 and the 200 day moving average is recorded at $10.55. S&P 500 has rallied 8.87% during the last 52-weeks. Rockwell Medical, Inc. (NASDAQ:RMTI) rose 3.9% or 0.55 points on Monday and made its way into the gainers of the day. After trading began at $14.35 the stock was seen hitting $14.66 as a peak level and $14.1101 as the lowest level. The stock ended up at $14.65. The daily volume was measured at 693,031 shares. The 52-week high of the share price is $14.95 and the 52-week low is $8.095. The company has a market cap of $735 million. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol. NO COMMENTS LEAVE A REPLY Cancel reply |
